AC Immune (NASDAQ:ACIU) unveiled clinical data on Friday suggesting its experimental vaccine could potentially slow the progression of Parkinson’s disease, a milestone that accompanied a significant corporate restructuring aimed at preserving its capital.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has secured a long-term financial runway, shifting focus toward pivotal data readouts for its lead gastrointestinal program following a successful fourth quarter and a transformative February financing.
Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.
ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
Burning Rock Biotech (NASDAQ:BNR) on Thursday reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing modest top-line growth alongside significant margin expansion and cost discipline in its precision oncology testing business.
Seres Therapeutics (NASDAQ:MCRB) delivered a rare profitable year in 2025, though the black ink was the result of a major divestiture rather than a surge in drug sales.
Harvard Bioscience (NASDAQ:HBIO) posted a heavy net loss for fiscal 2025, a result dominated by a one-time accounting charge that overshadowed a year of steady operational progress in its core specialized laboratory equipment business.
Village Farms International (NASDAQ:VFF) cemented its transition from a traditional greenhouse grower to a high-margin cannabis producer, reporting record consolidated net income of $21 million, or $0.19 per share, for the full year 2025.
Pharming Group (NASDAQ:PHAR) reported a significant shift in its financial trajectory for the full year 2025, posting total revenues of $376.1 million, a 27% increase over the previous year.
REGENXBIO (NASDAQ:RGNX) shared positive interim data from its Phase I/II AFFINITY DUCHENNE trial on Wednesday, bolstering the case for its gene therapy candidate, RGX-202.
CVS Health's (NYSE:CVS) insurance unit, Aetna, has agreed to pay $117.7 million to resolve allegations that it defrauded the U.S. government by submitting inaccurate diagnosis codes for Medicare Advantage enrollees.
Citius Oncology (NASDAQ:CTOR) reported positive topline results on Tuesday from an investigator-initiated Phase 1 clinical trial evaluating its flagship immunotherapy, LYMPHIR (denileukin diftitox-cxdl), in combination with Merck’s pembrolizumab (Keytruda).
